No alteration in plasma IL-6 concentration was observed .
Pentoxifylline did not alter BP or plasma IL-6 concentration , but significantly reduced circulating TNF-α and CRP concentrations
INTRODUCTION Pentoxifylline is a xanthine derivative with potential cardiovascular benefits .
AIM To evaluate the impact of pentoxifylline on  blood pressure ( BP )  and plasma TNF-α , C-reactive protein ( CRP ) and IL-6 through a systematic review and meta- analysis of r and omized controlled trials .
Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial.
Diabetic kidney disease ( DKD ) is the leading cause of ESRD . We conducted an open-label , prospect i ve , r and omized trial to determine whether pentoxifylline ( PTF ) , which reduces albuminuria , in addition to renin-angiotensin system ( RAS ) blockade , can slow progression of renal disease in patients with type 2 diabetes and stages 3 - 4 CKD . Participants were assigned to receive PTF ( 1200 mg/d ) ( n=82 ) or to a control group ( n=87 ) for 2 years . All patients received similar doses of RAS inhibitors . At study end , eGFR had decreased by a mean±SEM of 2.1±0.4 ml/min per 1.73 m(2 ) in the PTF group compared with 6.5±0.4 ml/min per 1.73 m(2 ) in the control group , with a between-group difference of 4.3 ml/min per 1.73 m(2 ) ( 95 % confidence interval [ 95 % CI ] , 3.1 to 5.5 ml/min per 1.73 m(2 ) ; P<0.001 ) in favor of PTF . The proportion of patients with a rate of eGFR decline greater than the median rate of decline ( 0.16 ml/min per 1.73 m(2 ) per month ) was lower in the PTF group than in the control group ( 33.3 % versus 68.2 % ; P<0.001 ) . Percentage change in urinary albumin excretion was 5.7 % ( 95 % CI , -0.3 % to 11.1 % ) in the control group and -14.9 % ( 95 % CI , -20.4 % to -9.4 % ) in the PTF group ( P=0.001 ) . Urine TNF-α decreased from a median 16 ng/g ( interquartile range , 11 - 20.1 ng/g ) to 14.3 ng/g ( interquartile range , 9.2 - 18.4 ng/g ) in the PTF group ( P<0.01 ) , with no changes in the control group . In this population , addition of PTF to RAS inhibitors result ed in a smaller decrease in eGFR and a greater reduction of residual albuminuria
No alteration in plasma IL-6 concentration was observed .
Pentoxifylline did not alter BP or plasma IL-6 concentration , but significantly reduced circulating TNF-α and CRP concentrations
INTRODUCTION Pentoxifylline is a xanthine derivative with potential cardiovascular benefits .
AIM To evaluate the impact of pentoxifylline on  blood pressure ( BP )  and plasma TNF-α , C-reactive protein ( CRP ) and IL-6 through a systematic review and meta- analysis of r and omized controlled trials .